Jobs
-
Teva Pharmaceutical’s DuoResp Spiromax multidose DPI has won a Silver award at the 2015 Medical Design Excellence Awards (MDEA), with Gerresheimer receiving credit as a supplier. DuoResp Spiromax received European marketing authorization in April 2014.… Read more . . .
-
According to Boehringer Ingelheim, the United Kingdom, Croatia, Slovakia, Denmark, Norway, Ireland, Austria, Romania and Spain have approved the Spiolto Respimat tiotropium/olodaterol SMI for the treatment of COPD. BI recently announced the launch of the… Read more . . .
-
For podium presentations, submit 200-word summary by August 15, 2015 at http://www.rddonline.com/rdd/speaker_reg.php?id=12 For information on topics, see http://www.rddonline.com/rdd/rdd.php?id=12&sid=3 For posters, submit abstract by January 8, 2016. See http://www.rddonline.com/rdd/rdd.php?id=12&sid=4 for further information. Nominations for the Charles… Read more . . .
-
The Canadian Agency for Drugs and Technology in Health (CADTH) has issued a call for patient input regarding GSK’s Breo Ellipta fluticasone furoate/vilanterol DPI for the treatment of asthma. According to the announcement, the agency… Read more . . .
-
The Israeli Patent Office has issued Patent No. 193318, “System for Pulmonary Delivery of Alpha-1 Proteinase Inhibitor,” to Kamada and PARI Pharma, Kamada has announced. The patent relates to delivery of Kamada’s inhaled alpha-1 proteinase… Read more . . .
-
Boehringer Ingelheim Pharmaceuticals has announced the availability of the Stiolto Respimat tiotropium bromide/olodaterol soft mist inhaler in the United States. Stiolto Respimat was approved by the FDA for the treatment of COPD in May 2015.… Read more . . .
-
Current AstraZeneca Vice President Respiratory, Inflammation & Autoimmunity James Ward-Lilley will become CEO of Vectura Group as of October 1 2015. Vectura had previously announced that its current CEO, Chris Blackwell, will be stepping down… Read more . . .
-
OptiNose has announced positive results from the 24-week Phase 3 trial of OPN-375, an intranasal fluticasone product for the treatment for nasal polyps based on the company’s Bi-Directional Breath-Powered delivery system. The study showed statistically… Read more . . .
-
Copley Scientific has announced the publication of a brochure titled “Quality Solutions for Inhaler Testing, 2015 Edition” which includes a guide for testing of novel and generic OINDPS. The brochure includes an introduction to various… Read more . . .
-
US-based Novoteris has received a $2.8 million award from Cystic Fibrosis Foundation Therapeutics Inc. (CFFT) for development of Thiolanox inhaled nitric oxide therapy for the treatment of bacterial lung infections in cystic fibrosis patients. The… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden